Predicting drug-resistant mutations to improve cancer treatment
Official title: Quantitatively predicting drug-resistant mutations to improve precision oncology
Funded at Sloan-Kettering Inst Can Research · NIH-11016975 · Data updated 2026-11-12
This study is looking at how specific changes in proteins that help cancer cells grow can make treatments less effective, and it aims to find out about these changes before starting therapy so that doctors can create more personalized and effective treatment plans for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $144,056 |
| NIH project number | 5K99CA286801-02 |
| Project ID | NIH-11016975 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients whose tumors exhibit specific kinase mutations that may affect their response to treatment.
✕Less likely to help
Patients without kinase mutations or those whose cancer is not driven by kinase signaling may not benefit from this research.
What this research studies
This research focuses on understanding how certain mutations in protein kinases, which are crucial for cancer signaling, can lead to resistance against cancer therapies. By using advanced modeling techniques, the research aims to predict these mutations before treatment begins, allowing for more personalized and effective treatment plans. The approach combines structural analysis and quantitative assessments to evaluate how these mutations affect drug binding and efficacy. Ultimately, this work seeks to enhance precision oncology by improving the matching of therapies to individual tumor profiles.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by anticipating and overcoming drug resistance.
How similar studies have gone: Previous research has shown promise in using structural and quantitative methods to predict drug resistance in cancer therapies, indicating that this approach could be effective.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Singh, Sukrit — Sloan-Kettering Inst Can Research
- Study coordinator: Singh, Sukrit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.